26,037 results match your criteria: "M. D. Anderson Cancer Center.[Affiliation]"

Background: Appendiceal cancer is a rare disease that has proven difficult to study in prospectively. Our initial report of this trial showed minor hematologic toxicity with both mitomycin C and oxaliplatin and similar 3-year survival. We now report an update of the first prospective randomized trial for appendiceal cancer with 10-year follow up.

View Article and Find Full Text PDF
Article Synopsis
  • * Research is examining ways to lessen treatment intensity (de-escalation), particularly to reduce side effects from radiotherapy while maintaining effective cancer management for HPV-positive patients.
  • * Although some Phase II trials show promise for de-escalation strategies, current Phase III trials have not yet shown improved outcomes, indicating a need for more research and better risk assessment before these strategies can be routinely used outside clinical trials.
View Article and Find Full Text PDF

For phase II clinical trials that determine the acceptability of an experimental treatment based on ordinal toxicity and ordinal response, most monitoring methods require each ordinal outcome to be dichotomized using a selected cut-point. This allows two early stopping rules to be constructed that compare marginal probabilities of toxicity and response to respective upper and lower limits. Important problems with this approach are loss of information due to dichotomization, dependence of treatment acceptability decisions on precisely how each ordinal variable is dichotomized, and ignoring association between the two outcomes.

View Article and Find Full Text PDF

Background: While female survivors of Hodgkin lymphoma (HL) have an increased risk of breast cancer (BC), no BC risk prediction model is available. We developed such models incorporating mean radiation dose to the breast or breast quadrant-specific radiation doses.

Methods: Relative risks and age-specific incidence for BC and competing events (mortality or other subsequent cancer) were estimated from 1194 Dutch five-year HL survivors, treated at ages 11-40 during 1965-2000.

View Article and Find Full Text PDF

Background: Limited treatment options exist for inoperable thyroid cancers. We evaluated whether neoadjuvant use of systemic tyrosine kinase inhibitors facilitates surgery of differentiated thyroid cancers in this challenging context.

Methods: A single-institution experience of 42 patients receiving tyrosine kinase inhibitors for papillary, follicular and anaplastic thyroid carcinomas between 2018 and 2023 was reviewed to identify differentiated thyroid cancers treated with neoadjuvant tyrosine kinase inhibitors (dabrafenib/trametinib, lenvatinib/pembrolizumab, or lenvatinib alone) via multidisciplinary protocols.

View Article and Find Full Text PDF

Disease-modifying therapies are standard of care (SOC) for sickle cell disease (SCD), but hematopoietic cell transplantation (HCT) has curative potential. We compared outcomes prospectively through 2-years after biologic assignment to a Donor or No Donor (SOC) Arm based on the availability of an HLA-matched sibling or unrelated donor (BMTCTN 1503; NCT02766465). A donor search was commenced after eligibility confirmation.

View Article and Find Full Text PDF
Article Synopsis
  • - The study reviews current immunotherapy approaches for small bowel neuroendocrine tumors (SBNET) and explores future avenues for better treatment responses
  • - Key treatments like somatostatin analogs and mTOR inhibitors are essential, while new applications of peptide receptor radionuclide therapy (PRRT) show promise, though existing immunotherapies have had limited success
  • - Increased incidence of SBNET highlights the need for more effective therapies, and further research into the immune microenvironment may uncover new targets for improved patient outcomes
View Article and Find Full Text PDF

Importance: The impact of patient-specific, disease-related, and social factors on outcomes in limited-stage small cell lung cancer (LS-SCLC) is not well defined. A post hoc secondary analysis of such factors from the Cancer and Leukemia Group B (CALGB) 30610-Radiation Therapy Oncology Group (RTOG) 0538 trial may impact future trial design.

Objective: To assess the comprehensive demographic, disease-related, treatment-related, and social factors for potential associations with survival outcomes and understand whether specific subpopulations may benefit from radiotherapy (RT) dose escalation in LS-SCLC.

View Article and Find Full Text PDF

Therapeutic approaches to modulate the immune microenvironment in gliomas.

NPJ Precis Oncol

October 2024

Center for Neuro-Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA.

Article Synopsis
  • Immunomodulatory therapies, especially immune checkpoint inhibitors, have improved cancer treatment outcomes over the past decade, but gliomas show limited response to these therapies due to their complex immune microenvironment.
  • * The glioma immune microenvironment includes various cells such as macrophages, myeloid-derived suppressor cells, neutrophils, microglia, and lymphocytes, which contribute to the ineffective response to existing treatments.
  • * Recent efforts focus on understanding this unique environment and developing new therapies, including oncolytic viruses, vaccines, and cell-based therapies like CAR-T and CAR-NK cells, which are currently in clinical trials.
View Article and Find Full Text PDF

Antibiotic-induced microbiome dysbiosis is widespread in oncology, adversely affecting outcomes and side effects of various cancer treatments, including immune checkpoint inhibitors and chimeric antigen receptor T (CAR-T) cell therapies. In this study, we observed that prior exposure to broad-spectrum ABX with extended anaerobic coverage like piperacillin-tazobactam and meropenem was associated with worsened anti-CD19 CAR-T therapy survival outcomes in large B-cell lymphoma patients (n=422), compared to other ABX classes. In a discovery subset of these patients (n=67), we found that the use of these ABX was in turn associated with substantial dysbiosis of gut microbiome function, resulting in significant alterations of the gut and blood metabolome, including microbial effectors such as short-chain fatty acids (SCFAs) and other anionic metabolites, findings that were largely reproduced in an external validation cohort (n=58).

View Article and Find Full Text PDF

Misregistration between CT and PET in PET/CT is mainly caused by respiratory motion or irregular respiration during the CT scan in PET/CT. Other than repeat CT, repeat PET/CT, or data-driven gated (DDG) CT, there is no practical approach to mitigate the misregistration artifacts and subsequent CT attenuation correction (CTAC) of the PET data. DDG PET derives a respiratory motion model based on the multiple phases of PET images without hardware gating and it allows for a potential correction of the misregistration artifacts based on the respiratory motion model.

View Article and Find Full Text PDF

Purpose: The topical administration of spironolactone, a mineralocorticoid receptor antagonist (MRA) improves dry eye symptoms in patients with ocular graft-versus-host disease (GVHD); however, the detailed mechanism remains unclear. This study aimed to investigate the effects of spironolactone eyedrops on the ocular surface using a chronic GVHD (cGVHD) mouse model and to determine the expression of the mineralocorticoid receptor (MR).

Methods: A cGVHD mouse model was established by allogeneic bone marrow transplantation (BMT) from B10.

View Article and Find Full Text PDF

IRE1α silences dsRNA to prevent taxane-induced pyroptosis in triple-negative breast cancer.

Cell

December 2024

Department of Experimental Therapeutics, James P. Allison Institute, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA; Department of Molecular and Cellular Biology, Lester and Sue Smith Breast Center, Dun L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA. Electronic address:

Article Synopsis
  • Chemotherapy combined with immune checkpoint inhibitors (ICIs) is used to boost immunotherapy effectiveness, but certain tumors, especially triple-negative breast cancer (TNBC), often remain unresponsive.
  • The study identifies IRE1α, an ER stress sensor, as a key factor that limits the immune-boosting effects of taxane chemotherapy in these tumors by silencing double-stranded RNA (dsRNA) and preventing a type of inflammatory cell death called pyroptosis.
  • Inhibiting IRE1α allows taxane to produce more dsRNA, which activates immune responses, transforming PD-L1-negative TNBC tumors into ones that are sensitive to immunotherapy.
View Article and Find Full Text PDF

Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma.

N Engl J Med

October 2024

From City of Hope Comprehensive Cancer Center, Duarte (A.F.H., M.G.M., J.Y.S.), University of California Davis Comprehensive Cancer Center, Sacramento (J.M.T.), and Children's Hospital Los Angeles, Los Angeles (C.F., A.D., A.K.) - all in California; SWOG Statistics and Data Management Center, Fred Hutchinson Cancer Center, (M.L., H.L.) and Seattle Children's Hospital (A.L.) - both in Seattle; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta (S.M.C.), and Winship Cancer Institute and Emory University Hospital (K.A.B.), Atlanta; Weill Cornell Medicine (S.C.R., J.P.L.), Memorial Sloan Kettering Cancer Center (P.T.), and New York University Langone (L.K.S.), New York, Wilmot Cancer Institute, University of Rochester, Rochester (C.C., L.S.C., J.W.F.), and Roswell Park Comprehensive Cancer Center, University at Buffalo, Buffalo (K.M.K.) - all in New York; Rutgers Cancer Institute of New Jersey, New Brunswick (A.M.E.); McGill University Health Centre, Montreal (K.D.), and SickKids Hospital (Angela Punnett) and Princess Margaret Cancer Centre (D.H., Anca Prica, M.C.), Toronto - all in Canada; Reid R. Sacco AYA Cancer Program, Tufts Medical Center (S.K.P.), and Dana-Farber Cancer Institute (M.A.S.) - both in Boston; M.D. Anderson Cancer Center, Houston (S.A.), and University of Texas Health Science Center at San Antonio, San Antonio (S.K.) - both in Texas; Siteman Cancer Center, Washington University, St. Louis (N.L.B., B.K.); Medical University of South Carolina, Charleston (B.T.H.), and Prisma Health Cancer Institute - Eastside, Greenville (S.C.) - both in South Carolina; Carolinas Medical Center, Levine Cancer Institute, Charlotte, NC (R.J.); Moffitt Cancer Center, Tampa (H.S.), and Sylvester Comprehensive Cancer Center, University of Miami, Miami (C.M.) - both in Florida; Huntsman Cancer Institute, University of Utah, Salt Lake City (B.H.); University of Alabama at Birmingham, Birmingham (G.G.); Illinois CancerCare, Peoria (P.K.), and University of Chicago, Chicago (S.M.S.); Cancer and Hematology Centers of Western Michigan, Grand Rapids (B.B.), and University of Michigan, Ann Arbor (A.M.P.); the Department of Hematology and Oncology, Geisinger Community Medical Center, Scranton, PA (N.S.); Fairview Ridges Hospital, Minnesota Oncology, Burnsville (A.S.); SWOG Cancer Research Network, Teaneck, NJ (H.D.); and the National Cancer Institute, Cancer Therapy Evaluation Program, Bethesda, MD (R.F.L.).

Article Synopsis
  • Brentuximab vedotin has been shown to improve outcomes in treating advanced classic Hodgkin's lymphoma, but it also causes more toxic side effects in adults, while many pediatric patients still need radiation therapy and face challenges with relapse.
  • A phase 3 trial involving patients aged 12 and older tested two treatment combinations: brentuximab vedotin with standard chemotherapy (BV+AVD) versus nivolumab with standard chemotherapy (N+AVD), aiming to assess progression-free survival.
  • Results indicated that N+AVD significantly enhances progression-free survival compared to BV+AVD, with a 2-year survival rate of 92% for N+AVD versus 83% for BV
View Article and Find Full Text PDF

Impact of Six Months of Three Different Modalities of Exercise on Stress in Post-Treatment Breast Cancer Survivors.

Cancers (Basel)

October 2024

Department of Population Health Sciences, Institute for Health Promotion Research, University of Texas Health-San Antonio, 7411 John Smith Drive, Suite 1000, San Antonio, TX 78229, USA.

Background/objectives: Extensive evidence suggests that exercise is physically and mentally beneficial for cancer survivors. This study reports on changes in self-reported stress, physiological biomarkers for stress (salivary cortisol), and HR-QOL constructs for fifty breast cancer survivors participating in one of three different exercise programs over 6 months.

Methods: Fifty post-treatment breast cancer survivors were randomized to either therapeutic yoga-based exercise (YE), comprehensive exercise (CE) (aerobic, resistance, flexibility), or choosing (C) their own exercise activities.

View Article and Find Full Text PDF

Recommended guidelines for screening for underlying malignancy in extramammary Paget's disease based on anatomic subtype.

J Am Acad Dermatol

February 2025

Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois. Electronic address:

Article Synopsis
  • Extramammary Paget's disease (EMPD) can be linked to underlying internal adenocarcinomas, with varying associations based on the EMPD subtype.
  • A systematic literature review identified that perianal EMPD has a higher rate (25%) of associated adenocarcinomas compared to penoscrotal and vulvar types (6% each).
  • The proposed screening algorithms suggest specific tests based on EMPD subtype, emphasizing thorough screening for high-risk perianal cases and more cost-effective approaches for lower-risk penoscrotal and vulvar cases.
View Article and Find Full Text PDF

Introduction: In this study, we evaluate the association between sociodemographics and disease presentation, treatment, and survival for children, adolescents, and young adults with Ewing sarcoma.

Methods: Case-level data were downloaded from The Surveillance, Epidemiology, and End Results database. Cases included patients ages 0-24 who were diagnosed with Ewing sarcoma between 2004 and 2020.

View Article and Find Full Text PDF

Leucine-Rich Alpha-2-Glycoprotein 1 Promotes Metastatic Colorectal Cancer Growth Through Human Epidermal Growth Factor Receptor 3 Signaling.

Gastroenterology

October 2024

Department of Surgery, Case Western Reserve University, Cleveland, Ohio; Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio; Department of Surgery, Division of Surgical Oncology, University Hospitals Cleveland Medical Center, Cleveland, Ohio. Electronic address:

Article Synopsis
  • Therapy failure in metastatic colorectal cancer (mCRC), particularly in the liver, is a significant issue; new strategies are needed as existing HER3-targeting therapies have underperformed in clinical settings.
  • Research focused on how liver-derived factors, specifically leucine-rich alpha-2-glycoprotein 1 (LRG1), trigger a non-canonical HER3 activation pathway, facilitating CRC growth independent of traditional HER3 signaling.
  • Targeting the LRG1-HER3 interaction may offer novel treatment options for mCRC, showing promise for improving patient outcomes and tackling liver metastases.
View Article and Find Full Text PDF
Article Synopsis
  • The COVID-19 pandemic affected many countries and led to strict health rules that caused economic problems too.
  • Researchers studied how international flights influenced the spread of COVID-19 using a special computer model called Dynamic Weighted GraphSAGE (DWSAGE).
  • Their findings showed that areas like Western Europe, the Middle East, and North America had a big impact on the pandemic due to lots of air traffic, and they suggested ways to reduce flights to help control it.
View Article and Find Full Text PDF

Introduction: Cancer survivors experienced poorer health-related quality of life (HRQoL) and greater psychological distress during the COVID-19 pandemic than those without cancer. However, the underlying mechanisms that may explain how negative experiences during the pandemic are associated with distress and HRQoL remain unknown. We examined whether psychosocial risk factors (i.

View Article and Find Full Text PDF

Introduction: Accelerated hypofractionated radiotherapy has gained increasing interest for locally advanced NSCLC, as it can potentially increase radiobiologically effective dose and reduce health care resource utilization. Nevertheless, there is sparse prospective evidence supporting routine use of accelerated hypofractionation with or without concurrent chemotherapy. For this reason, the International Association for the Study of Lung Cancer Advanced Radiation Technology Subcommittee conducted a systematic review of prospective studies of accelerated hypofractionation for locally advanced NSCLC.

View Article and Find Full Text PDF

Non-small-cell lung cancer.

Nat Rev Dis Primers

September 2024

Airway Research Center North, German Center of Lung Research, Grosshansdorf, Germany.

Non-small-cell lung cancer (NSCLC) is one of the most frequent cancer types and is responsible for the majority of cancer-related deaths worldwide. The management of NSCLC has improved considerably, especially in the past 10 years. The systematic screening of populations at risk with low-dose CT, the implementation of novel surgical and radiotherapeutic techniques and a deeper biological understanding of NSCLC that has led to innovative systemic treatment options have improved the prognosis of patients with NSCLC.

View Article and Find Full Text PDF

Pancreatitis pain quality changes at year 1 follow-up, but GP130 remains a biomarker for pain.

Pancreatology

November 2024

Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, School of Medicine, University of Pittsburgh, PA, United States.

Background/objectives: Debilitating abdominal pain is a common symptom affecting patients with chronic pancreatitis (CP). CP pain is dynamic due to multiple underlying mechanisms. The objective of this study was to 1) evaluate changes in pain phenotype at one year follow-up and 2) validate putative pain biomarkers in a prospective cohort study.

View Article and Find Full Text PDF

In 2018, a "survival cliff" in the United States was identified among older adolescent and young adult (AYA) patients with acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL). This study reassessed the cliff and associated putative causes. Survival data were obtained using the U.

View Article and Find Full Text PDF